Laboratory Corporation of America Holdings (LH)

Investment Committee Summary

Investment Thesis

At $339 on 25 August 2026, LabCorp trades near 19 times forward earnings and a mid-cycle multiple of enterprise value to revenue — a price that assumes steady low-single-digit volume growth, an operating margin near 14%, and a continued bolt-on acquisition cadence. The engine does not dispute that base case; the base path lands close to the current quote. The disagreement is distributional rather than directional. Weighting a genuine reimbursement-impairment state and a volume-recession state against the combined specialty-diagnostics and acquisition upside leaves triangulated fair value at $222, a gap of -34% to spot, with the probability-weighted expected value at $281 and the twelve-month target at $270. The shares are trading rich to the weighted anchors, which is what produces the SELL. The independent discounted-cash-flow anchor is softer still, reflecting incremental returns on new capital below the cost of that capital and net debt of ~$6.3B that limits how much growth can be bought. The single most damaging risk is reimbursement: a fee-schedule cut compresses price with no volume offset and de-rates the multiple at the same moment.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($339) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear is structural rather than cyclical. LabCorp is a price-taker facing government fee-schedule pressure and payers steering volume to hospital and in-house laboratories. In that path organic volume turns negative, the operating margin near 14% erodes on fixed-cost deleverage, and the market stops paying a mid-cycle multiple for a shrinking, reimbursement-exposed base. Carrying net debt of ~$6.3B, the balance sheet then works against the company: leverage limits the acquisitions that have masked thin organic growth, and buybacks compete with deleveraging for the same cash. The multiple compresses toward a distressed level on falling earnings, taking the structural target below the 52-week low. Simulated outcomes finishing above the current price sit at the low end of the plausible band, which is a caution on the calibration rather than a licence to ignore the direction. This is a genuine impairment mechanism, not a token hedge.

Key Debate

Gross Margin explains 58% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 18.5× consensus forward EPS, vs the house DCF terminal 13.0×, and a peer median 14.5×. The house DCF sits 50% below spot, so the market is pricing in more than the house case — roughly 3.9pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily multiple-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Reimbursement / In-House Testing' downside ($120) to a 'Bull — Re-Rate' bull case ($519); the probability-weighted blend (PWEV $281) is -17% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.9% of revenue; free cash flow net of SBC is $1.08B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Reimbursement / In-House Testing (20%, $120). Structural impairment — reimbursement / insourcing: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Volume Recession (17%, $203). Cyclical downturn — outsourced service volume + reimbursement per unit + mix + tuck-in M&A weakens for 1–2 years before normalising.
• Base — Volume + Acquisitions (35%, $290). Mid-cycle — normalised outsourced service volume + reimbursement per unit + mix + tuck-in M&A; disciplined capital allocation; steady returns.
• Growth — Advanced-Diagnostics / M&A (20%, $398). Upside — mix upgrade + M&A lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $519). Upside tail — sustained tight conditions or a structural re-rate on mix upgrade + M&A.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $249 and 26% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (58% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 13.0x terminal FCF multiple → $169. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $129; the peer-median forward P/E is 14.5x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 61% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Diagnostics & Outsourced Health Services multiple (AI re-rating) (base 15.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 15.1× (simple median 14.5×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $239–$339, centre $285 (-16% vs spot); spot sits at the 100th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $519.

Company Overview & Business Model

Laboratory Corporation of America Holdings — HEALTHCARE · DIAGNOSTICS & RESEARCH. Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories.

How it makes money.

Edge. Narrow moat — LabCorp's moat is narrow — national testing-network scale, logistics density and payer/health-system contracts create a real cost and access advantage in a duopoly-ish routine-testing market, but reimbursement is set by payers/CMS (PAMA) and in-house/point-of-care testing chips at volume; a narrow moat supports the ~15x forward mid-cycle lab multiple, and if reimbursement cuts or insourcing accelerate the terminal multiple should compress toward the low-teens rather than re-rate on advanced-diagnostics optionality.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 187% — cash-backed.

Competitive Moat

Moat sources:

• National lab network scale, logistics and patient-service-centre density (cost/access moat)
• Long-term managed-care and hospital-outreach contracts
• Effective duopoly with Quest in routine clinical testing
• Advanced-diagnostics / oncology capability and biopharma-CRO relationships (optionality, not yet a moat)

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.35 vs analyst floor +0.00 → delta +0.35 (n=24 mgmt / 13 Q&A; 39th pctile across the S&P book, z -0.3).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1280 articles): avg ticker sentiment +0.21 (bullish 25% / bearish 1%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2027-01-20 (~149d) — Advanced-diagnostics (oncology/companion Dx) commercial milestone (authored)

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +2.6%.
• Prior-forecast backtest (12 snapshots, 2026-06-27→2026-08-20): directional hit-rate 0%; mean predicted -9.5% vs realised +13.7%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

5 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic diagnostics volume growth (ex-M&A, ex-COVID), YoY < 0.0 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Diagnostics adjusted operating margin < 0.128 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Medicare/commercial reimbursement rate change on the top test panel, YoY < -0.03 (single event). A PAMA-style or fee-schedule cut beyond low-single-digits directly funds the Structural scenario, hitting price with no volume offset.
• Net leverage (net debt / EBITDA) > 3.0 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Advanced/esoteric-test revenue share of Diagnostics < 0.0 (2 consecutive prints). The Growth and Bull paths require mix-shift into higher-margin advanced testing; a stalling or declining specialty share removes the margin lever that separates them from the Base case.

Fact / Inference / Speculation

• FACT: Spot $339; 52-week range $239–$339; engine rating SELL; house target $270 (-20%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $222 (-34% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

54.0/100 (confidence band 39.9–68.0), 33rd percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 54.3 → 54.3 → 54.0 → 53.8 → 53.8 → 53.6 → 54.2 → 54.2.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $281.05.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.34, vs QQQ +0.21 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Protective Put. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish/holder — hedge the position; a collar finances the put by capping upside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 45th percentile of the cross-section → mid vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 62nd percentile of its own month-end history (decile 7).
• IV term structure is in contango (longer-dated richer, slope +2.0pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.

IV term structure (contango, slope +2.0pp): 25-DTE 24% · 88-DTE 26% · 270-DTE 26%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Collar, Put Debit Spread. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 23.9% (moderate regime) · expected move ±4.6% (2026-09-18) · put/call OI 0.80 · ATM Δ 0.52 / Θ -0.16 / ν 0.35. Direction: SHORT/HEDGE (implied return -34.5% to triangulated fair value $222.36).

Bear Put Spread (Bearish) — Long 340 P / Short 240 P · 2027-02-19 · net debit $19.3 · max profit $80.70 · breakeven $320.70 · RoR 418.0% · max loss $19.30 · priced from the listed chain (EOD marks)

Defined-risk downside expression: the debit caps the loss, with the position gaining as the stock falls toward the lower strike — a way to act on a bearish view without shorting stock. Illustrative — no outcome is implied or guaranteed.

Protective Put (if held) (Hedge) — Long 340 P · 2027-02-19 · premium $21.1 · floor 0.0% · max loss $21.10 · priced from the listed chain (EOD marks)

Insurance for an existing holding — a known premium buys a floor while leaving the upside intact. A way to hold through a binary event or volatility with defined downside.

Protective Collar (if held) (Hedge) — Long 310 P / Short 370 C · 2027-02-19 · net $2.65 · floor -9.0% · cap +9.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -17% vs spot
• Monte Carlo median implies -26% vs spot
• DCF fair value implies -50% vs spot — but this is terminal-value sensitive (exit-multiple $169 vs Gordon $223, 32% apart), so it carries less weight
• Bear case (Structural — Reimbursement / In-House Testing) downside is -65% vs spot
• Net: the valuation anchor itself sits 34.5% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $6B + PV(terminal) $14B = EV $20B; − net debt $6.3B → equity $14B ÷ diluted shares $0.08B = $169/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $223/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 9% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $129 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (111.0); Revenue CAGR ±3pp (65.0); Terminal × ±15% (51.0); Capex intensity ±15% (26.0); WACC ±1pp (20.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 13×, FY+5 revenue $16B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.